• LOGIN
  • SUBSCRIBE
  • FREE E-Newsletter/Product Bulletins

Cath Lab Digest

  • Follow us on
  • Home
  • About Us
    • Privacy Policy/Copyright
    • About VDM
  • Issues
    • Current Issue
    • Issue Archives
  • Editor's Update
  • Advertise
  • Reprints
  • Authors
    • Author Instructions
    • Submission Portal
  • Reviewers
  • Contact

Search

FDA Approves Boston Scientific's Express® LD Iliac Stent System

First and only premounted, balloon-expandable stent approved specifically for use in iliac arteries

Boston Scientific Corporation (Natick, Massachusetts) announced that the U.S. Food and Drug Administration (FDA) has approved its Express® LD Iliac Premounted Stent System for use in iliac arteries. The Express LD Iliac Stent is the first and only low-profile, premounted, balloon-expandable stent approved by the FDA for use in treating iliac artery disease. The Company said it plans to launch the product immediately in the United States.
The Express LD Iliac Stent is designed to be highly deliverable, and its Tandem Architecture™ Stent Design is engineered to balance strength, flexibility and conformability.

Atherosclerotic iliac disease occurs when plaque builds within the arteries that supply blood to the legs, which can lead to poor blood flow, leg pain and other complications. The disease can be treated with medication, surgery or angioplasty.

"Boston Scientific's Express LD Iliac Stent incorporates a flexible stent design and is engineered for improved deployment accuracy, two critical treatment components," said Barry Katzen, MD, FACR, FACC, of Baptist Cardiac and Vascular Institute in Miami. "With an approved iliac indication, the Express LD Stent offers physicians a less-invasive alternative to surgery for our patients suffering from iliac artery disease."

"The Express LD Iliac Stent offers an attractive option for physicians treating the iliac arteries," said Joe Fitzgerald, Senior Vice President and President of Boston Scientific's Endovascular Unit. "This approval reinforces our leadership in the treatment of peripheral artery disease and adds to our portfolio of peripheral vascular stent indications, which includes the Carotid WALLSTENT® Endoprosthesis for carotid artery disease and the Express® SD Stent for renal artery disease."

The Express LD Iliac Stent has received CE Mark approval and is currently approved for iliac use in a number of international markets.

"I have found that the benefits of a balloon-expandable stent like the Express LD Iliac Stent can be extremely important when working in atherosclerotic iliac lesions," said Luc Stockx, MD, of Limburgs Vaatcentrum Ziekenhuis, Belgium. "Deployment accuracy and radial strength can play crucial roles in these types of procedures, and the Express LD Stent is designed to deliver both."

For more information, please visit: http://www.bostonscientific.com/

image description image description


				

  • Advertise your Job Here
    For information on posting classified ads, please contact:
    Alex Dulnikowski, Classified Sales Manager
    (800) 237-7285, ext. 205

vdm Blogs

PROTECT carotid stent trial provides further evidence that CAS is getting better and becoming more competitive with CEA

Frank J Criado MD FACS FSVM

A New Algorithm to Treat Patients with Peripheral Vascular Disease

Robert S. Dieter MD RVT and Aravinda Nanjundappa MD RVT

In-Stent Restenosis in the SFA Remains a Significant Unresolved Problem

Frank J Criado MD FACS FSVM

Support Comes From Many Directions

Richard R. Heuser MD FACC FACP FESC FSCAI

Pedal Artery Access: Advances in Management of Critical limb ischemia

Robert S. Dieter MD RVT and Aravinda Nanjundappa MD RVT
more »

Vascular Newswire

  • Boston Scientific Launches Innovative Crossing Device to Treat Complete Blockages in Peripheral Arteries
    Fri, 02/10/12 - 11:12am
  • Stereotaxis Announces European Adoption Milestone and Health Canada Market Clearance for Vdrive System
    Fri, 02/10/12 - 11:08am
  • Medtronic Stent Resulted in 90% Freedom from Reinterventions in Narrowed Leg Arteries at 12 Months in International Study
    Thu, 02/09/12 - 10:52am
  • AngioDynamics Launches DuraFlow 2 Chronic Hemodialysis Catheter
    Wed, 02/08/12 - 10:18am
more »

Clinical Events Calendar

  • American Venous Forum 24th Annual Meeting
    Wed, 02/08/2012 - Sat, 02/11/2012
    Orlando, FL, United States
  • JIM 2012
    Thu, 02/09/2012 - Sat, 02/11/2012
    Rome, Italy
  • Cardiovascular Care Update 2012 (CVC)
    Fri, 02/10/2012 - Sat, 02/11/2012
    Scottsdale, AZ, United States
more »

Poll

How do you feel about the continued practice of screening patients for asymptomatic CAD?:
REVIEW OUR OTHER Cardiology BRANDS

Our other resources for healthcare professionals.

HMP Communications © 2012 HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. ©2012 HMP Communications